Advertiser








   


Shattered Self
Depression takes its toll locally,
but treatment is disjointed.

By Elizabeth Pownall

In January 2000, the Surgeon General reported that "among the developing nations, including the U.S, major depression is the leading cause of disability." Nineteen million people were diagnosed with depression in 1998 and women are affected by depression two times more than men, according to the National Institute of Mental Health (NIMH).

Statistics indicate that 30 million people have been on Prozac at least once in their lives, and millions more on other anti-depressants. In a recent study by Harvard researchers and the World Health Organization, it is projected that by the year 2020 depression could claim more years of people's useful life than war and AIDS.

Coping With
Our Lives

PI remember the day Prozac came into our lives just as clearly as I can remember the day JFK was shot. It was at night. We lived in a small town. We had a 1-year-old and I was pregnant with our second child. My husband, a physician, had just come home from work and showed me a medical report on this "miracle drug" that treats depression with minimal side affects. This was in 1992. Up until then we had never talked about depression.

As we approach 2001 I see in my family a radical change from 1992. As I will never forget the day the word Prozac came into our lives, I will never forget the day, four years later, when I went on Paxil for postpartum depression. Although my experience with medication was brief, it gives me some insight into the use of antidepressants in our culture. I felt my personal stigma attached to the diagnosis of depression. I felt the leap it takes when one goes on the medicaiton. I remember the challenge it was to find an appropriate therapist while in the throes of depression. And I remember the courage it took to go off the medication.

As tools to enable us to cope with our lives, SSRI's are miracle drugs. As placebos to help us merely cope, critics say they silence us. How will we, as patients who rely on our doctor's sound advice, deal with the miracle drugs which actually do smooth out the surface of our lives, when they are handed us?
Are we, as Whybrow asks, eradicating sadness in our culture's on-going pursuit of pleasure, or are we, as responsible human beings, trying to cope with and make sense of the "swiftly tilting planet" upon which we live?

„ Elizabeth Pownall
These statistics are alarming when we consider our attitude toward depression. There is still such a social stigma surrounding the disease that it silences us and kills us, writes psychiatrist Dr. Peter Whybrow in his book, A Mood Apart. When we can speak openly about mental illness and mood disorders, he says, we will be able to recognize them for what they are „ human suffering driven by dysregulation of the emotional brain.

A new name for depression might be "hypothalamo-pituitary-adrenal-axis dysfunction", suggests NIMH neuroscientist Philip Gold. "People confuse (the word depression) with the everyday sensation of feeling despondent and dismiss it."

We run into problems when we think that we can control full-blown, set-in depression. However, writes Whybrow, depression is a disability of the mind when it is affected by a disordered mood. We blame it on loss of willpower, or a lack of self-discipline when actually, "our coherent image of the world is a unique interactive process between the brain's biology and what we experience. Each can change the other." To truly face depression as an illness of the mind, he says, we need to accept that it has biological underpinnings. It can be triggered by stressful events, but only in someone who has, what Whybrow calls, a "neurobiological Achilles heel."


The Shattering of the Self
Depression is a prolonged sense of grief. And grief, Whybrow believes, is a "shattering" of oneself. It is difficult to recognize oneself in depression because of one's distorted self-reflection. All of the housekeeping elements such as cognitive thought, memory, concentration, and decision-making, are disturbed when one is depressed.

Our limbic system, or emotional center of our brain, is still as ancient as it was in the saber tooth tiger days. We deal with stressful situations as we did then „ with our fight-or-flight response. However, Whybrow says, our actual presence of danger has changed. Danger was once uncertainty about the animals in the dark forest surrounding our camp; now about the dark forest in our mind. Our fears are more deeply psychological, hidden, bearing no physical form. Depression, he believes, originates from our inability to cope effectively with this uncertainty and our broken connections from one another. When one feels a part of the tribe, one is safe and can deal with the uncertainty of the surrounding forest.

"We don't have the same basic fears as other people in war-torn areas," says OSU Professor Cydreese Aebi, R.Ph, Ph.D, "and yet the stressors can be equally as strong. They are different stressors for us. The complexity of our lives, the complexity of our society „ while people in Israel worry about being shot by stray bullets, the stress can cause the same reaction in our body when we worry about something else."
"Since depression is a mental illness you end up with a lot of shame around it," says Alice Duffy, Licensed Clinical Social Worker (LCSW) in Eugene, "There's a lot of stigma, a lot of hiding behavior so it's almost better to have mom be a drunk than mom be depressed."

We do not admit readily to an illness or disability of the mind, however, we will yield more easily to the fragility of our aging bodies. "We cling," Whybrow says, "to invincibility in spirit."


No Class Boundaries
Depression cuts across class lines, says Dr. Gary LeClair, obstetrician/gynecologist (ob/gyn) at All Women's Health Care in Eugene. "Depression is not how good it is, depression is intrinsic. It doesn't matter how good things are, you are still depressed."

The upper middle class is usually the last group of people to be diagnosed with depression, and yet, Aebi says, "Some say that depression hits the higher income bracket even more (than other social classes) .... nobody is really immune to it."

"I have been in practice for 30 years," says LeClair,"and I definitely see more depression. I think it's the pace of our society. I think things move past our face so quickly. You have Iinternet, e-mail, now everybody's got cell phones. It used to be if you weren't home, nobody would talk to you ... There is a real loss in the stability here, in America."
Drug Pushers
Caution: This advertising may be dangerous to your health.
By Debra Merskin

Feel like you're seeing more advertisements for prescription drugs than ever before? You are. Know more about Bob Dole's erectile dysfunction than you'd like? Oh yeah.

Not only are these ads annoying but the costs are significant -- to both the drug companies and the consumers who want what's being advertised. In 1999, U.S. drug companies spent nearly $2 billion urging people to try prescription remedies for everything from allergies and baldness to high-cholesterol and diabetes. That's more than other companies spend advertising cereal, beer, or luxury resorts.

The goal, of course, is to get patients to go to their doctor and demand a brand-name drug, even though generic is cheaper. Because many HMOs will not cover brand-name drugs, consumers end up paying for them themselves There is little competition to motivate drug companies to lower prices and with the advertising costs passed on to the consumer at an estimated 12 percent, those drugs are expensive.

Yet sales information suggests that these ads are successful. A recent survey shows that 88 percent of patients commonly asked for a particular drug by brand name. Claritin, the #1 direct-to-customer (DTC) advertiser, earned $2.3 billion; Prilosec, one of the top five, enjoyed $3.8 billion in sales. A recent calculation shows that, with the Glaxo Wellcome & SmithKline Beecham merger, the resulting company will have the third highest global ad spending campaign after Coca-Cola and Anheuser Busch.

Direct-to-customer advertising has increased in recent years for a couple of reasons. Pressure from pharmaceutical companies, managed care providers, and advertisers caused the FDA in 1997 to substantially relax restrictions on what could be said and shown in pharmaceutical advertising. Before that, complex FDA restrictions meant people only saw ads for problems no more severe than hair loss.

Today, at least 50 prescription drugs are promoted on television and radio (the media of choice) -- closer to 100 if print advertising is included. The FDA requirements are fairly simple: TV and radio ads only have to mention a drug's major risks and four follow-up sources of information -- "your doctor, a toll-free number, a web site, and a concurrent print ad."
This sounds simple enough, but the FDA has cited several ads for "lack of balance, incomplete information, or misleading claims." Since Aug. 1997, of the 50 drugs that have been advertised, 23 regulatory letters were sent to drug companies for drug ads that violated FDA rules.

These ads included those for the heartburn remedy Prevacid and the anti-allergy nasal spray Flonase. But these warnings are typically sent well after the ads have appeared on national television and in magazines. Why after? Although the FDA is still the oversight organization, ads do not need to be pre-approved by the agency.

Companies are required to send a copy of the ad to the FDA whenever a new one debuts and the FDA must review the ad within 15 days of receipt. An ad can get a lot of exposure in 15 days. As is the case in many governmental agencies, the FDA is overbooked: Last year alone, a 16-member staff was responsible for screening about 30,000 pieces of promotional material and more than 100 TV commercials.

So, are we, as patients, better informed or, as consumers, helping to sustain misinformation and illusions of miracle cures? The arguments go both ways.
Supporters of pharmaceutical advertising say the benefits to society are many. One argument is that consumers have become more involved with their healthcare. A 1998 Prevention survey found that 53 million consumers have talked with their physicians about a medicine they saw advertised. The availability of the Internet further facilitates consumer information gathering. Twenty years ago it was considered unethical to advertise medicines (other than aspirin) and taboo to question the advice of a health care provider. Supporters say that having information in hand has changed the way doctors and patients talk about medicines, removing some of the mystique of going to the doctor.

Finally, supporters argue that people are more likely to seek treatment for what ails them. This is particularly the case for asthma, migraines, depression, and irritable bowel syndrome. Depression is one disease that often goes untreated and the ads encourage people (mostly women) to seek treatment.
Critics voice several concerns: that DTC advertising exaggerates the effectiveness of medications, leading consumers to believe in miracle cures. They also say the ads downplay a drug's risks by focusing only on its benefits; that they encourage Americans to believe that pills, rather than lifestyle changes or non-drug interventions, are the treatment of choice; and that the ads encourage consumers to ask for a drug by name.

With managed care programs limiting doctors' time, prescriptions are written at a far greater rate than ever before, with little time for doctors to study their effectiveness. The ads encourage doctors to prescribe medicines that may not be appropriate. According to one survey, about 75 to 80 percent of the time a patient asks for a specific drug, he or she receives it. A final criticism is that DTC advertising becomes a "hypochondriac's charter." Doctors already deal with patients armed with Internet printouts describing various diseases and treatments. Now people come in with ads detailing the medications they want.

Although some people are more vulnerable to media messages than others, supporters of pharmaceutical advertising say that general consumer attitudes toward advertising are skeptical and that people will seek out other sources of information rather than believe advertising. The question remains whether consumers have the time, energy, resources, and general medical knowledge required to assess product claims and risks for a blood pressure medication with the same ease as a laundry detergent. Nobel Prize winner George Stigler wrote that advertising "is an immensely powerful instrument for the elimination of ignorance." If so, at what price?



Debra Merskin is an associate professor at the UO School of Journalism & Communication.

Dr. Cristin Babcock, ob/gyn at All Women's Health Care in Eugene, agrees. "In 1970," she says, "one income bought the average American house. By 1990, it took two average incomes to buy one average American house „ so to have those things we consider normal, both parents have to work which means there's going to be increased stress in people's lives."

Depression can be an intrinsically genetic predisposition, it might be a result of environmental life stress, or it can be a result of inertia; knowing something in one's life is not working, and not taking the initiative to make positive changes, says Duffy. It can also mask other medical, metabloic or social problems such as eyesight problems, hormonal changes, domestic violence, substance abuse, etc.

When Alexander Solomon went through a serious bout of depression he was told it could be cured by medication, he writes in his New Yorker article "Anatomy of Melancholy." However, this is not true, he says. "Depression these days is treatable; you take antidepressants the way you take chemotherapy for cancer."

When patients are first diagnosed by their primary care physician with depression they are in one of their most vulnerable moments. Herein lies the new role of physicians prescribing psychiatric medication. While physicians do not have the time, nor the training to counsel their patients, they hold what could be a very powerful responsibility in helping their patients find the type of help they need. If the physician or nurse can help a patient, says Aebi, "just with that first appointment, it would be very beneficial for that patient."


The Therapy Gap
Studies show that drug therapy coupled with psychotherapy is considered optimal treatment for depression. However, there is a gap between the physician's and therapist's office. The new antidepressants work so well at enabling patients to safely cope with their lives with a minimal amount of side effects that many patients use them and go on living their stressful lives.

The most disturbing trend is that people will try medication first rather seek out therapeutic help, says Dr. William Balsom, family practice physician in Eugene. Patients do not seek help for a myriad of reasons, he says. "They have time and money constraints, they are embarrassed, or they have limited or no access because of their health insurance benefits," he says.

Insurance access has made it difficult for the patient to receive counseling, says LeClair. Patients are often confused as to how they obtain counseling. Many believe they must go through their physician when that is usually not the case. Quite often, he went on, even if they have the preferred provider list from their insurance company, the patient does not know who to call.

"I don't think we can use pharmacotherapy as a crutch," Aebi believes," I think we need to really delve in and see what the cause is „ if we can find the cause. ... That's where the physician, and the psychiatrist or the counselor really work together. Drug therapy is just one part of it," she says.

Typically the mental health and medical community reside parallel to one another. There is very little crossover due to the confidentiality of patient information in therapy, and the time constraint under which physicians operate. However, this is an important aspect of health care that needs to be addressed, says Dr. Rupert Goetz, medical director of the Office of Mental Health Services for the state of Oregon. "There is no solution to depression", he says, "but any communication across the primary care/mental health interface between elements of programs, the providers, and the patients are critical pieces of the puzzle."

In her four years of private practice in Eugene, Duffy finds that when she can establish contact with physicians, her clients get the most advantageous care. "I've had more than one physician that I have had to call and say, excuse me but your patient is suicidal," she says. "They may not be scheduled to see that patient for another 15 days. Patients are afraid of disturbing the doctor and by the time someone gets suicidal, they don't necessarily want a lot of help."

"Given a clear and and plausable alternative to suicide, I find that depressed people rarely want to die," says Dr. David Shaw, a Seattle psychiatrist who specializes in mood disorders. "People are just looking for some relief from the incredible sort of distress clinical depression causes."


The New Meds
Prior to the late 1980's, tricyclics were the only medications available to treat depression. They are so named because of their three-ring chemical structure. Tricyclics came with many severe side effects, including the danger of overdose, says Aebi. It was hard to treat depression with tricyclics, she went on, because patient compliance was poor. "There were a lot more office visits, a lot more emergency room visits ... we had a lot of deaths due to tricyclic antidepressant overdose," she says.

The new antidepressants or selective serotonin reuptake inhibitors (SSRI's) such as Prozac, came on the market in the late 1980s. Serotonin is one of three neurotransmitters that balances the chemistry of mood, the other two being norepinephrine and dopamine. SSRI's and many other mood altering drugs, achieve their effect by mimicking neurotransmitters' activity, thus changing the chemical balance in the brain. The difference between tricyclics and the newer antidepressants is that while tricyclics affect many neurotransmitters, or brain signal chemicals, the newer ones affect only three: serotonin, norepinephrine and dopamine systems. The beauty of SSRI's is that because side effects are substantially fewer, they are easier and more safe for physicians to prescribe and for patients to use, Aebi explains.

Over the last eight years SSRI's such as Zoloft, Paxil, and Prozac have become household names. However, each drug is unique, as is each individual taking them. It is crucial that physicians work with their patients to find the medication most suitable. For instance, explained Aebi, Prozac might cause agitation in one, but might be suitable for someone else. Paxil might cause drowsiness in some patients, but in others it might effectively treat their anxiety.

As the patients will feel the immediate side effects of the medication first, such as nausea and a lowered libido, and the mood elevation later, they might get discouraged and want to try another medication. It could take up to five weeks before any therapeutic effects are noticeable, notes Shaw.

"We see too many prescriptions for too many changes too quickly. You won't see dramatic results overnight. That's just the way they work," says Aebi," They are not harsh in the body. ... We're trying to work slowly to have the system readjust itself."

"They are very gentle and very slow in the brain," Aebi explained. "We're not just putting in a vitamin and all of a sudden replenish the body ... we're working with neurotransmitters that have to reestablish an electrical pathway and network. It takes some time for the body to do that. That's why they are very gentle and have less side effects."

The risk of a drug overdose or toxic side effect with the SSRI's is nearly non-existent so visits to the emergency rooms have decreased, she says. Follow-up visits to the doctor once a patient is on the medication is scheduled in terms of weeks, rather than days as it was with the tricyclics.

There will always be side effects to pharmaceuticals, no matter what the drug companies do to refine the medication, says Aebi. "We have neurotransmitters all over our body," she says. "Anytime you put any chemical in the body „ whether it be health food chemical or a manufactured chemical from a drug company „ it's going to affect some other system in your body. Aspirin affects blood; you may take it for one specific thing, but it is affecting a lot of other areas in your brain and body."


Depression and Hormones
Research on depression and brain chemistry is starting to examine the role hormones play in women approaching menopause. While some research indicates that the decline of estrogen as a woman goes through her perimenopausal transition might trigger a mood disorder, other research indicates that there is no decline and that mood disorders in this time period of a woman's life have more to do with life situation, says Babcock.

"Hormones may have an effect," she says, "but there is more to it. As a gynecologist, I think of it as parallel tracks and not necessarily related. So you have your female hormones and they may make you more miserable or less miserable but the depression track is a different track and it's going to go along regardless of what is happening hormonally."

However, Aebi disagrees, "up until the last 5-10 years we didn't even consider horomones and mental health diseases nearly as much. I think medicine has geared itself toward men and men's diseases for so long that we're just coming around and seeing that we haven't treated women the same."

At this point, Aebi believes, hormone levels are not as useful as predictors of depression. It is more, she believes, that there is a connection with depression. This is the "next place we really need to look", she says.


Table of Contents | News & Views | Arts & Entertainment
Classifieds | Personals | EW Archive